Beam Therapeutics Inc.

18.48
0.84 (4.79%)
At close: Apr 02, 2025, 3:59 PM
17.15
-7.22%
After-hours: Apr 02, 2025, 07:58 PM EDT

Beam Therapeutics Statistics

Share Statistics

Beam Therapeutics has 99.84M shares outstanding. The number of shares has increased by 21.3% in one year.

Shares Outstanding 99.84M
Shares Change (YoY) 21.3%
Shares Change (QoQ) 20.57%
Owned by Institutions (%) 98.87%
Shares Floating 88.04M
Failed to Deliver (FTD) Shares 8.8K
FTD / Avg. Volume 0.5%

Short Selling Information

The latest short interest is 10.79M, so 13.03% of the outstanding shares have been sold short.

Short Interest 10.79M
Short % of Shares Out 13.03%
Short % of Float 14.86%
Short Ratio (days to cover) 8.25

Valuation Ratios

The PE ratio is -5.42 and the forward PE ratio is -5.36. Beam Therapeutics's PEG ratio is -0.03.

PE Ratio -5.42
Forward PE -5.36
PS Ratio 32.14
Forward PS 3.4
PB Ratio 2.78
P/FCF Ratio -5.73
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Beam Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.22.

Current Ratio 4.82
Quick Ratio 4.82
Debt / Equity 0.22
Debt / EBITDA -0.39
Debt / FCF -0.45
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $131.51K
Profits Per Employee $-780K
Employee Count 483
Asset Turnover 0.06
Inventory Turnover n/a

Taxes

Income Tax 39K
Effective Tax Rate -0.01%

Stock Price Statistics

The stock price has increased by -37.74% in the last 52 weeks. The beta is 1.91, so Beam Therapeutics's price volatility has been higher than the market average.

Beta 1.91
52-Week Price Change -37.74%
50-Day Moving Average 26.15
200-Day Moving Average 25.67
Relative Strength Index (RSI) 31.79
Average Volume (20 Days) 1.77M

Income Statement

In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.

Revenue 63.52M
Gross Profit 63.52M
Operating Income -415.57M
Net Income -376.74M
EBITDA -415.57M
EBIT -415.57M
Earnings Per Share (EPS) -4.58
Full Income Statement

Balance Sheet

The company has 281.97M in cash and 161.43M in debt, giving a net cash position of 120.54M.

Cash & Cash Equivalents 281.97M
Total Debt 161.43M
Net Cash 120.54M
Retained Earnings -1.57B
Total Assets 1.1B
Working Capital 696.08M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -347.25M and capital expenditures -8.95M, giving a free cash flow of -356.19M.

Operating Cash Flow -347.25M
Capital Expenditures -8.95M
Free Cash Flow -356.19M
FCF Per Share -4.33
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -654.25% and -593.13%.

Gross Margin 100%
Operating Margin -654.25%
Pretax Margin -593.06%
Profit Margin -593.13%
EBITDA Margin -654.25%
EBIT Margin -654.25%
FCF Margin -560.77%

Dividends & Yields

BEAM pays an annual dividend of $1.12, which amounts to a dividend yield of 4.8%.

Dividend Per Share $1.12
Dividend Yield 4.8%
Dividend Growth (YoY) 0%
Payout Ratio -24.56%
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BEAM is $42, which is 127.3% higher than the current price. The consensus rating is "Buy".

Price Target $42
Price Target Difference 127.3%
Analyst Consensus Buy
Analyst Count 12
Stock Forecasts

Scores

Altman Z-Score 0.44
Piotroski F-Score 2